By Fineline Cube 
Shanghai Stexo Biotechnology Co., Ltd. announced that its proprietary extracellular vesicle drug STX11101 injection, derived from human adipose-derived mesenchymal stem cells, has received clinical trial approval from the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for the treatment of acute liver failure.
Regulatory Milestone & Product Profile
| Item | Detail |
|---|---|
| Company | Shanghai Stexo Biotechnology Co., Ltd. |
| Product | STX11101 injection (extracellular vesicle/exosome therapy) |
| Source | Human adipose-derived mesenchymal stem cells |
| Classification | Cell-free Advanced Therapy Medicinal Product (ATMP) |
| Indication | Acute liver failure |
| Regulatory Body | CDE/NMPA (China) |
| Approval Date | 6 July 2026 |
| Intellectual Property | Global rights held by Stexo |
Technology Platform & Therapeutic Innovation
- Extracellular Vesicle Platform: STX11101 represents a cell-free therapeutic approach that harnesses the regenerative and immunomodulatory properties of extracellular vesicles (exosomes) without the complexities and risks associated with whole-cell therapies.
- Mechanism of Action: The therapy delivers bioactive cargo—including proteins, lipids, and nucleic acids—from mesenchymal stem cells to damaged hepatocytes, promoting tissue repair, reducing inflammation, and modulating immune responses in acute liver injury.
- Manufacturing Advantage: As a cell-free product, STX11101 offers improved scalability, consistency, and storage stability compared to traditional cell-based therapies, potentially enabling broader clinical accessibility.
Acute liver failure represents a critical unmet medical need with limited treatment options beyond liver transplantation, creating significant opportunity for novel regenerative approaches.
Development Strategy & Market Positioning
First-in-Class Potential: STX11101 appears to be among the first extracellular vesicle therapies to advance to clinical development in China for acute liver failure, positioning Stexo at the forefront of this emerging therapeutic modality.
Global Rights Strategy: With worldwide intellectual property protection, Stexo maintains full commercial flexibility to pursue international partnerships or independent development beyond China following successful clinical proof-of-concept.
Regulatory Pathway: The NMPA’s classification as an Advanced Therapy Medicinal Product (ATMP) provides access to expedited review mechanisms and specialized regulatory guidance, potentially accelerating time-to-market.
Clinical & Commercial Outlook
- Trial Design: Initial Phase I/II studies will focus on safety, dosing optimization, and preliminary efficacy signals in acute liver failure patients.
- Market Opportunity: China accounts for approximately 30% of global acute liver failure cases, with an estimated 50,000-100,000 annual incidents and high mortality rates despite current standard of care.
- Competitive Landscape: The extracellular vesicle therapeutics space remains relatively nascent globally, with few competitors advancing beyond preclinical development for liver indications.
Forward‑Looking Statements
This brief contains forward-looking information regarding clinical development, regulatory approvals, and market opportunities. Actual results may differ due to clinical trial outcomes, regulatory decisions, manufacturing challenges, and competitive developments.-Fineline Info & Tech